XORTX Therapeutics Reports Financial Results for Mid-2025

XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an announcement.

XORTX Therapeutics Inc. released its condensed interim consolidated financial statements for the three and six months ended June 30, 2025. The report highlights a decrease in total assets from $4,094,527 at the end of 2024 to $2,742,018 by June 2025, alongside a reduction in total liabilities. The financial results indicate a challenging period for the company, with increased expenses in research and development and investor relations, impacting its financial position and potentially its market strategy.

The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.

Spark’s Take on TSE:XRTX Stock

According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.

XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.

To see Spark’s full report on TSE:XRTX stock, click here.

More about XORTX Therapeutics Inc

XORTX Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of therapies for kidney disease, diabetes, and other health conditions. The company is known for its innovative approach in addressing unmet medical needs through its proprietary technology and drug development programs.

Average Trading Volume: 4,184

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$4.47M

For a thorough assessment of XRTX stock, go to TipRanks’ Stock Analysis page.